Alzheimer drugs ruled to be cost effective according to NICE

The National Institute for Health and Clinical Excellence (NICE) ruled that Alzheimer’s disease medications are cost effective and should be available on prescription. If the draft decision is upheld, three drugs – Aricept, Exelon and Reminyl – would be available on the National Health System (NHS) for people in the early and moderate stages of Alzheimer’s disease. These treatments have up to now been restricted to people in the moderate stages. A fourth drug, called Ebixa, would also be made available to people in the moderate to late stages.
NICE is inviting people to comment on the draft decision by 28 October, with a second meeting of the Appraisal Committee taking place on 25 November. The latest decision has been taken as part of a review cycle of Alzheimer’s drug treatments by NICE.

**Published by "Alzheimer Europe"